SUBSCRIBE: eNewsletter
In an older patient wtih T2DM, HFpEF, and other comorbidities, which class of medication is guideline-recommended?
Cardiovascular outcomes trials of diabetes drugs have led to label expansions and guideline endorsements. Do you recall the studies and the outcomes? Find out, here.
The SGLT2 inhibitor, on October 21, 2019 was granted a label expansion from FDA for the prevention of hospitalization for heart failure in patients with T2D.
For people with type 2 diabetes, receiving motivational messages via mobile text was associated with reduced A1c vs patients who received usual care.
Less than half of PCPs responding to a recent survey chose correct values for prediabetes screening tests and seemed unaware of other evidence-based recommendations for prediabetes.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
About 25% of patients with diabetes report asking a physician for a cheaper drug. Skipping doses and pill splitting are tactics used to cut costs.
When intensifying T2DM therapy to reach glycemic goals, newer agents target common comorbidities. Which would you choose in these 3 scenarios?
In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?
![](https://www.patientcareonline.com/sites/default/files/styles/trc_article_348x228/public/SGL1.JPG?itok=xehRklLj "<p><em><strong>The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. Newer diabetes medications also hit that spot.</strong></em></p>")
The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.
ADA 2019 ICYMI: Tirzepatide, a GIP and GLP-1 receptor agonist, reduces A1c and BMI as well as biomarkers of metabolic dysfunction in type 2 diabetes patients. Four studies reviewed.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
